The primary grounds for exclusion were interventions other than GLP-1 agonists, the inclusion of adult participants, participants with secondary causes of obesity, and participants with diabetes, unrelated to obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.